•Multiple myeloma patients have poor serological responses after influenza vaccination.•Treatment with daratumumab (anti-CD38) does not seem to further impair such response.•A boosted vaccination ...could have a positive impact on humoral responses.•Future research is needed for innovative prophylaxis strategies in these patients.
Daratumumab-treated myeloma patients may face increased seasonal influenza risk due to weakened postvaccination immune responses, especially with daratumumab treatment. We aimed to assess humoral responses to boosted influenza vaccination in daratumumab-treated or -untreated patients.
In a single-center study, we evaluated humoral responses (hemagglutination-inhibition assay) one month following a two-injection (4-weeks apart) influenza vaccination (standard dose) in 84 patients with multiple myeloma (40 with daratumumab in the past year).
Seroprotection rates (titer ≥1/40) after the second vaccine injection were low across vaccinal subtypes (except for A-H3N2): 71.3% (A-H3N2), 19.7% (A-H1N1pdm09), 9.9% (B-Victoria), 11.3% (B-Yamagata). Only A-H3N2 seroprotection rates significantly increased with the booster in daratumumab-treated patients (30% (12/40) after one injection vs 55% (22/40) after the boost; P = 0.01).After propensity score weighting, daratumumab was not significantly associated with a reduced likelihood of seroprotection against at least one vaccine strain (OR 0.65 95% CI: 0.22-1.88).
While daratumumab treatment did not lead to a significant reduction in seroprotection rates following influenza vaccination, a booster vaccine injection demonstrated potential benefit for specific strains (A-H3N2) in patients undergoing daratumumab treatment. Nevertheless, the overall low response rates in patients with multiple myeloma necessitates the development of alternative vaccination and prophylaxis strategies.
A previous pilot study with rituximab, gemcitabine and oxaliplatin showed promising activity in patients with refractory/relapsed B-cell lymphoma. We, therefore, conducted a phase II study to ...determine whether these results could be reproduced in a multi-institutional setting. This phase II study included 49 patients with refractory (n=6) or relapsing (n=43) diffuse large B-cell lymphoma. The median age of the patients was 69 years. Prior treatment included rituximab in 31 (63%) and autologous transplantation in 17 (35%) patients. International Prognostic Index at enrollment was >2 in 34 patients (71%). The primary endpoint was overall response rate after four cycles of treatment. Patients were planned to receive eight cycles if they reached at least partial remission after four cycles. After four cycles 21 patients (44%) were in complete remission and 8 (17%) in partial remission, resulting in an overall response rate of 61%. Factors significantly affecting overall response rate were early (<1 year) progression/relapse (18% versus 54%; P=0.001) and prior exposure to rituximab (23% versus 65%; P=0.004). Five-year progression-free and overall survival rates were 12.8% and 13.9%, respectively. Rituximab, gemcitabine and oxaliplatin were well tolerated with grade 3-4 infectious episodes in 22% of the cycles. These results are the first confirmation from a multicenter study that rituximab, gemcitabine and oxaliplatin provide a consistent response rate in patients with refractory/relapsed diffuse large B-cell lymphoma. This therapy can now be considered as a platform for new combinations with targeted treatments. This trial was registered at clinicaltrial.gov under #NCT00169195.
Enteropathy-associated T-cell lymphoma (EATL) is a rare but severe complication of coeliac disease (CeD), often preceded by low-grade clonal intraepithelial lymphoproliferation, referred to as type ...II refractory CeD (RCDII). Knowledge on underlying oncogenic mechanisms remains scarce. Here, we analysed and compared the mutational landscape of RCDII and EATL in order to identify genetic drivers of CeD-associated lymphomagenesis.
Pure populations of RCDII-cells derived from intestinal biopsies (n=9) or sorted from blood (n=2) were analysed by whole exome sequencing, comparative genomic hybridisation and RNA sequencing. Biopsies from RCDII (n=50), EATL (n=19), type I refractory CeD (n=7) and uncomplicated CeD (n=18) were analysed by targeted next-generation sequencing. Moreover, functional in vitro studies and drug testing were performed in RCDII-derived cell lines.
80% of RCDII and 90% of EATL displayed somatic gain-of-functions mutations in the JAK1-STAT3 pathway, including a remarkable p.G1097 hotspot mutation in the JAK1 kinase domain in approximately 50% of cases. Other recurrent somatic events were deleterious mutations in nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB) regulators TNFAIP3 and TNIP3 and potentially oncogenic mutations in TET2, KMT2D and DDX3X. JAK1 inhibitors, and the proteasome inhibitor bortezomib could block survival and proliferation of malignant RCDII-cell lines.
Mutations activating the JAK1-STAT3 pathway appear to be the main drivers of CeD-associated lymphomagenesis. In concert with mutations in negative regulators of NF-κB, they may favour the clonal emergence of malignant lymphocytes in the cytokine-rich coeliac intestine. The identified mutations are attractive therapeutic targets to treat RCDII and block progression towards EATL.
COVID-19 patients affected by haematological malignancies have a more severe course of the disease and higher mortality, prompting for effective prophylaxis. The present study aims to evaluate the ...humoral response after mRNA vaccination as well as the impact of a third vaccine dose in patients with lymphoid malignancies.
We conducted a single-centre study, evaluating the serological responses of mRNA vaccination amongst a cohort of 200 patients affected by lymphoid malignancies after two or three doses using an industrial SARS-CoV-2 serology assay for anti-receptor binding domain (RBD) Spike IgG detection and quantification.
Among patients with plasma cell disorders, 59 of 96 (61%) had seroconversion (anti-RBD >50 AU/mL), and recent anti-CD38 therapies were associated with lower serological anti-RBD IgG concentrations (median IgG concentration 137 (IQR 0–512) AU/mL vs. 543 (IQR 35–3496) AU/mL; p < 0.001). Patients with B-cell malignancies had a lower seroconversion rate (20/84, 24%) mainly due to the broad usage of anti-CD20 monoclonal antibodies; only 2 of 53 (4%) patients treated by anti-CD20 antibodies during the last 12 months experienced a seroconversion. A total of 78 patients (44 with plasma cell disorders, 27 with B-cell malignancies, and 7 with other lymphomas) received a third dose of vaccine. The seroconversion rate and antibody concentrations increased significantly, especially in patients with plasma cell disorders, where an increment of anti-RBD IgG concentrations was observed in 31 of 44 (70%) patients, with an anti-RBD concentration median-fold increase of 10.6 (IQR 2.4–25.5). Its benefit in B-cell malignancies is uncertain, with only 2 of 25 (8%) patients having seroconverted after the vaccine booster, without increased median antibody concentration.
A third mRNA vaccine dose significantly improved humoral responses among patients with plasma cell disorders, whereas the effect was limited among patients with B-cell malignancies.
Display omitted
From the Departments of Clinical Hematology (JD, TEG, IG, CH), Pathology and INSERM U617 (PG, CC-B), Biostatistics (FH), Nuclear Medicine (EI, MM), and Radiology (AR) - H. Mondor Hospital, Paris XII ...University, Assistance Publique-Hôpitaux de Paris (AP-HP), Créteil, France; Departments of Clinical Hematology (CG) and Pathology (JB), St-Louis Hospital, Paris VII University, AP-HP, Paris, France
Correspondence: Corinne Haioun, Service dHématologie Clinique, Hôpital H. Mondor, 51, Avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France. E-mail: corinne.haioun{at}hmn.aphp.fr
Background and Objectives: Diffuse large B-cell lymphomas (DLBCL) have a variable outcome, and powerful methods of prognostication are needed in order to choose the best treatment for each patient. Immunophenotypic classification of the tumor as germinal center (GC) or non-germinal center-like (nGC) and early response evaluation with 18 fluorodeoxyglucose positron emission tomography ( 18 FDG-PET) scanning have been correlated with survival in DLBCL but the two methods have never been evaluated simultaneously in the same patient population. Our aim was to investigate their respective prognostic values in the same series of patients.
Design and Methods: We investigated the expression of CD10, Bcl-6, and MUM1 in 81 patients with DLBCL evaluated early with 18 FDG-PET. The tumors were classified as GC or nGC using the algorithm of Hans et al . The results of both methods were correlated with the patients characteristics and survival.
Results: CD10 was positive in 27/76 (36%), Bcl-6 in 43/74 (58%), and MUM1 in 33/73 (45%) interpretable cases. Thirty-eight (51%) were in the GC group, and 36 (49%) in the nGC group. With a median follow-up of 33 months, estimated 3-year event-free survival (EFS) of the whole population was 67%. There was no influence of GC/nGC phenotype on survival. Three-year EFS was 46% in the early PET-positive group versus 80% in the PET-negative group ( p =0.0003).
Interpretation and Conclusions: The prognostic value of GC/nGC phenotype is not confirmed in this heterogeneous series, whereas early PET findings are confirmed to be a powerful predictor of outcome. The impact of treatment decisions based on early PET results should be evaluated.
Key words: diffuse large B-cell lymphoma, germinal center, immunohistochemistry, PET scan, prognosis.
Objective
To design a whole-body MR protocol using exclusively diffusion-weighted imaging (DWI) with respiratory gating and to assess its value for lesion detection and staging in patients with ...diffuse large B-cell lymphoma (DLBCL), with integrated FDG PET/CT as the reference standard.
Methods
Fifteen patients underwent both whole-body DWI (b = 50, 400, 800 s/mm
2
) and PET/CT for pretreatment staging. Lymph node and organ involvement were evaluated by qualitative and quantitative image analysis, including measurement of the mean apparent diffusion coefficient (ADC).
Results
A total of 296 lymph node regions in the 15 patients were analysed. Based on International Working Group size criteria alone, DWI findings matched PET/CT findings in 277 regions (94%) (kappa score = 0.85, P < 0.0001), yielding sensitivity and specificity for DWI lymph node involvement detection of 90% and 94%. Combining visual ADC analysis with size measurement increased DWI specificity to 100% with 81% sensitivity. For organ involvement, the two techniques agreed in all 20 recorded organs (100%). All involved organ lesions showed restricted diffusion. Ann Arbor stages agreed in 14 (93%) of the 15 patients.
Conclusion
Whole-body DWI with ADC analysis can potentially be used for lesion detection and staging in patients with DLBCL.
There is no established standard treatment for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in patients who are not eligible to receive an intensive treatment. The combination of ...rituximab gemcitabine and oxaliplatin (R-GemOx) is widely used in this population but data are scarce. We retrospectively collected the data of 196 patients with R/R DLBCL treated with R-GemOx in two French centers over a period of 15 years. The median age of the population was 72 years (range, 24-89), 63% of the patients had an international prognostic index of 3 or higher and 57% were refractory to the last treatment. At the end of R-GemOx treatment, 33% of the patients obtained a complete response. The median progression-free survival (PFS) of the population was 5 months and the median overall survival (OS) was 10 months. Several factors were predictors of unfavorable survival: age over 75 years, international prognostic index of 2 or higher, refractory disease and de novo DLBCL. The median PFS and OS of the patients who obtained a complete response were 22 months and 40 months, respectively. The most significant toxicities were grade 3-4 hematological toxicities (31% of patients). Given its efficacy and tolerability, R-GemOx can be used in patients ineligible for intensive treatment and serve as a basis for new regimen combinations.
Celotno besedilo
Dostopno za:
DOBA, IJS, IZUM, KILJ, NUK, PILJ, PNG, SAZU, UILJ, UKNU, UL, UM, UPUK
Primary GI T-cell lymphoproliferative diseases (T-LPD) are heterogeneous entities, which raise difficult diagnosis and therapeutic challenges. We have recently provided evidences that lymphomas ...complicating coeliac disease (CD) arise from innate-like lymphocytes, which may carry NK receptors (NKRs).
NKRs expression was compared by flow cytometry in intraepithelial lymphocytes (IEL) from CD, type I or type II refractory CD (RCD). NKp46 was next assessed by immunohistochemistry in paraffin-embedded biopsies from 204 patients with CD, RCDI, RCDII or GI T-cell lymphomas and from a validation cohort of 61 patients. The cytotoxic properties of an anti-NKp46 monoclonal antibody conjugated to pyrrolobenzodiazepine (PBD) was tested
in human primary tumour cells isolated from fresh duodenal biopsies.
NKp46 (but not CD94, NKG2A, NKG2C, NKG2D) was significantly more expressed by malignant RCDII IEL than by normal IEL in CD and RCDI. In paraffin biopsies, detection of >25 NKp46+ IEL per 100 epithelial cells discriminated RCDII from CD and RCDI. NKp46 was also detected in enteropathy-associated T-cell lymphomas (EATL, 24/29) and in monomorphic epitheliotropic intestinal T-cell lymphomas (MEITL, 4/4) but not in indolent T-LPD (0/15). Treatment with anti-NKp46-PBD could efficiently and selectively kill human NKp46+ primary IEL
.
NKp46 is a novel biomarker useful for diagnosis and therapeutic stratification of GI T-LPD. Strong preclinical rationale identifies anti-NKp46-PBD as a promising therapy for RCDII, EATL and MEITL.
Background :
High grade B cell lymphoma (HGBL) either Not Otherwise Specified (NOS) or either Double Hit (DH MYC/BCL2 or DH MYC/BCL6) or Triple Hit (TH) have been considered as separate entities from ...Diffuse Large B-Cell Lymphoma (DLBCL) NOS in the 2016 WHO classification. Until now, treatment of these particularly aggressive histological sybtypes remains unclear and most of patients (pts) still have a poor outcome because of chemoresistance or early relapse. Except IPI score, prognosis factors are not completely clarified. Since few years, treatment with Chimeric Antigen Receptor T (CAR-T) cells has changed the prognosis of relapsed refractory DLBCL and could represent a promising therapeutic approach - early in the course of the disease - to improve survival of HGBL. The aim of the present study is to describe a « real life » cohort of pts treated in our institution and to evaluate the prognostic impact of clinical, histological, genetic and imaging characteristics and treatment.
Methods :
We collected data of 45 pts diagnosed between January 2009 and October 2020. BCL2, BCL6 and MYC break were analyzed by Interphase Fluorescence In Situ Hybridization (FISH) with break-apart probes. When MYC was rearranged, MYC partner gene was analyzed with double fusion probes (MYC/IgH, MYC/IgL, MYC/IgK). Total metabolic tumor volume (TMTV) was calculated using fully automatic segmentation of lymphoma lesions by an artificial intelligence (P. Blanc-Durand, Eur J Nucl Med Mol Imaging, 2021).
All pts were treated with rituximab R-CHOP/CHOP-like regimens. Treatment was reinforced (intensive regimen) with high dose methotrexate (14 pts treated with RCOPADM and one with R-ACVBP) when they were considered fit enough. Autologous stem cell transplantation at 1st relapse was performed in 3 pts and 5 pts were treated with CAR-T cells at 2 nd relapse.
Results :
Baseline characteristics were as follows: median age 60 y (28-80), IPI 3-5 : n=33 (73%), CNS localization : n=8/42 (19%), bone marrow involvement : n=10/34 (22%).
Twenty-seven pts were DH lymphoma (MYC/BCL2: 18; MYC/BCL6: 9), 8 patients were TH-lymphoma and 10 were HGBL-NOS.
MYC rearrangement was detected in 40 cases with an immunoglobulin partner gene (IgH, IgL or IgK) in 14 (52%) of 27 evaluable cases.
TMTV was calculated for 29 pts with a median TMTV of 1019 ml (2-4536 ml). Fifteen pts were treated with an intensive regimen. With a median follow-up of alive pts of 17 months, 2-y progression-free survival (PFS) and overall survival (OS) were 42% 26.4 ; 56.8 and 62% 43.7 ; 75.5 respectively.
PFS and OS were significantly affected by IPI 3-5 (PFS: p= 0.006, HR=3.37 ; OS: p= 0.01, HR=3.71) and CNS involvement (PFS : p=0.006, HR=6.93 ; OS: p=0.006, HR=7.44). TMTV>1000ml (PFS: p=0.051, HR 2.99 ; OS: p=0.033, HR=4.13) was associated with a significantly inferior OS.
Prognosis of HGBL DH/TH and HGBL-NOS was similar (PFS: p= 0.89, HR=0.93 ; OS: p=0.64, HR=1.32). Immunoglobulin as MYC partner gene had no significant impact on prognosis (PFS: p=0.47, HR=1.48 ; OS: p=0.32, HR=1.73). Intensive regimens did not improve significantly prognosis (PFS: p=0.26, HR=1.71 ; OS: p=0.08, HR=2.86).
Conclusion:
This monocentric study confirms previous reports on the poor prognosis of HGBL (DH/TH and NOS) especially for patients for both high IPI or high TMTV and in case of initial CNS involvement.
We confirm that intensive regimen don't improve prognosis supporting the need of alternative strategies incorporating bispecific monoclonal antibodies or consolidative CAR-T cells in very high risk pts.
Roulin: Janssen: Other: Travel and meetings. Lemonnier: Institut Roche: Research Funding; Gilead: Other: travel grant. Le Bras: Novartis: Honoraria; Takeda: Honoraria, Research Funding; Kite Gilead: Honoraria; Celgene BMS: Research Funding. Gaulard: Innate Pharma: Research Funding; Sanofi: Research Funding; Alderaan: Research Funding; Gilead: Consultancy; Takeda: Consultancy, Honoraria. Haioun: Miltenyi: Honoraria, Research Funding; Gilead: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; F. Hoffmann-La Roche Ltd: Honoraria, Research Funding; Servier: Honoraria, Research Funding; Takeda: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Amgen: Honoraria, Research Funding.
Introduction: There is no standard treatment of refractory or relapsed (R/R) patients (pts) with DLBCL ineligible for autologous stem-cell transplantation (ASCT). However, R-GemOx is widely used in ...these circumstances.
We here report the results of a retrospective analysis of a cohort of patient treated in two academic centers in France. The main objectives were to evaluate the activity and safety profile of this regimen in a large series of R/R DLBCL pts in a real life setting.
Methods:
Patients selected had to have de novo or transformed DLBCL, R/R after at least one line of treatment containing doxorubicin and rituximab, to be ineligible for ASCT and to have received at least one cycle of R-GEMOX. Rituximab 375 mg/m2 was administered on D1, gemcitabine 1000 mg/m2 on D2 and oxaliplatin 100 mg/m2 on D2 as previously described (Mounier N. et al. Haematologica 2013; 98:1726-31). Cycles were given every 2 weeks and 8 cycles were planned if at least a partial response (PR) was obtained after 4 cycles.
Results:
Between May 2002 and May 2017, 196 pts were treated. Baseline characteristics were: median age: 72 y (range, 24-89), international prognostic index (IPI) 3-5: 63%, refractory state to last treatment (tx): 42%, history of indolent lymphoma: 45%, prior ASCT: 16%. The median number of previous line was 1 (range 1-7) with 112 pts having received R-GemOx in second line. One hundred and thirty-six pts received at least 4 cycles, 86 pts completed 6 cycles and 61 pts 8 cycles. After 4 cycles, the overall response rate (ORR) according to IWC (Cheson 1999 or 2007) was 54 % and the complete response (CR) rate was 23 %. At the end of treatment, the ORR and CR rates were 38 % and 33 %, respectively. With a median follow-up of 22 months, median (m) progression-free survival (PFS) and overall survival (OS) were 5 and 10 months (mo), respectively. mOS was significantly longer in case of prior history of indolent lymphoma (21 vs 8 mo, p < 0.001), age<75y (16 v 7mo, p < 0.001), IPI <3 (p < 0.001), non-refractory status to last treatment (18 v 7mo, p < 0.001). The mOS of patients who attained a CR was 40 mo. Among pts who were treated with R-GemOx in second line, the CR rate was similar (32%), the same factors influenced the OS and duration of a first remission longer than 12 months was a favorable factor (p=0.006). Based on data collected from the population who received the first four cycles, (136 patients and 848 cycles) the median received dose intensities of oxaliplatin and gemcitabine were 73.1 %, and 75.8% of the theoretical dose, respectively. The most common toxicities during treatment were hematological and manageable. Grade 3-4 toxicities occurred in 30.6% of pts. Grade 1-2 peripheral neuropathy related to oxaliplatin was observed in 26% of the patients, with only 2 patients presenting a grade 3 peripheral neuropathy.
Summary/Conclusion: This real life study of R/R DLBCL, confirms the activity and safety of R-GemOx. This combination represents a platform to be combined with targeted therapies as it is currently proposed with nivolumab in the phase 3 NIVEAU trial (NCT03366272) and planned with polatuzumab vedotin (POLARGO trial). However, facing this very high unmet medical need, new approaches including CAR T-cells should also be considered in this patient population.
Belhadj:Janssen: Honoraria; Celgene: Honoraria, Other: personal fees from Celgene, personal fees from Amgen, personal fees from Takeda, personal fees from Janssen, outside the submitted work; Takeda: Honoraria; Amgen: Honoraria. Le Bras:Pfizer: Other: Travel grant; Takeda: Research Funding; Jansen: Other: Travel grant. Jardin:amgen: Honoraria; Servier: Honoraria; celgene: Honoraria; roche: Honoraria; janssen: Honoraria. Tilly:Roche: Consultancy; Celgene: Consultancy, Research Funding; Astra-Zeneca: Consultancy; Karyopharm: Consultancy; BMS: Honoraria; Janssen: Honoraria; Gilead: Honoraria; merck: Honoraria; servier: Honoraria; roche: Membership on an entity's Board of Directors or advisory committees. Haioun:F. Hoffmann-La Roche Ltd: Honoraria; Novartis: Honoraria; Janssen: Honoraria; Gilead: Honoraria; Amgen: Honoraria; Celgene: Honoraria; Servier: Honoraria; Miltenyi: Honoraria; Takeda: Honoraria.